IGRAs: Can They Replace the TST?
National Web-based Seminar
January 28, 2009
San Francisco, California

*Presented live via the Internet
11:00 a.m. – 12:30 p.m. (Pacific Time)*

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:07</td>
<td>Course Overview</td>
<td>Kelly Smith and Lisa Chen</td>
</tr>
<tr>
<td>11:07-11:15</td>
<td>Introduction to IGRAs</td>
<td>Neil Schluger</td>
</tr>
<tr>
<td>11:15-11:40</td>
<td>IGRA Use in Special Situations: Review of Currently Available Data</td>
<td>Charles Daley</td>
</tr>
<tr>
<td>11:40-11:55</td>
<td>Serial Testing and Use of Quantitative Results</td>
<td>Randall Reves</td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Implementation</td>
<td>Masae Kawamura</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Question &amp; Answer Period</td>
<td>Faculty Panel</td>
</tr>
<tr>
<td>12:30</td>
<td>Closing</td>
<td>Kelly Smith</td>
</tr>
</tbody>
</table>
OBJECTIVES

By the end of this seminar, participants will be able to:

1. Compare and contrast IGRAs to the tuberculin skin test in terms of the test mechanics (how the test works).

2. Describe why one test may be more accurate to use in the BCG-vaccinated population over the other.

3. Describe the current data related to IGRA use in TB contacts, HIV disease, and in children.

4. Describe the implications of IGRA test conversions to "positive" and of reversions to "negative."

5. Describe why definitions of TST conversion, requiring a minimum increase in induration, were developed for serial testing and the implications for "standard" IGRA thresholds for positive.

6. Describe why the agreement (kappa values) of tests for LTBI will be poor in low-risk populations.

7. List two potential advantages to the clinical implementation of IGRA use.

8. List at least one common misconception regarding the advantages of IGRA use.
IGRAS: CAN THEY REPLACE THE TST?

National Web-based Seminar
January 28, 2009
San Francisco, California

FACULTY

Lisa Chen, M.D.
Medical Director,
Francis J. Curry National TB Center
Assistant Clinical Professor,
Pulmonary and Critical Care Division
University of California, San Francisco
San Francisco, California

Charles Daley, M.D.
Professor of Medicine,
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, Colorado

Masae Kawamura, M.D.
Tuberculosis Controller/Director,
TB Control Section,
San Francisco Department of Public Health
Co-principal Investigator,
Francis J. Curry National Tuberculosis Center
University of California, San Francisco
San Francisco, California

Randall Reves, M.D., M.P.H.
Medical Director,
Metro Denver TB Control Program
Professor,
Department of Preventive Medicine and
Biometrics,
University of Colorado Health Science Center
Denver, Colorado

Neil Schluger, M.D.
Professor of Environmental Health Sciences and
Professor of Epidemiology,
Mailman School of Public Health
Professor of Medicine,
College of Physicians and Surgeons
Chief,
Division of Pulmonary, Allergy, and Critical Care Medicine,
Columbia University Medical Center
New York, New York
IGRAS: CAN THEY REPLACE THE TST?

National Web-based Seminar
January 28, 2009
San Francisco, California

DECLARATION OF DISCLOSURE

The following course faculty members have indicated that they have not had any financial arrangements or affiliations with commercial sponsors which have direct interest in the subject matter:

Lisa Chen, M.D.

Masae Kawamura, M.D.

Randall Reves, M.D., M.P.H.

Neil Schluger, M.D.

--------------------------------------------------

Charles Daley, M.D. will be presenting information on Interferon-gamma Release Assays. Dr. Daley serves as a consultant for Cellestis and for Oxford-Immunotec. He has received a research grant from Oxford-Immunotec to fund non-tuberculosis related work with IGRAs.